- Home
- ZONE vs KZIA Comparison
ZONE vs KZIA Comparison
Compare ZONE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZONE
- KZIA
- Stock Information
- Founded
- ZONE 2022
- KZIA 1994
- Country
- ZONE United States
- KZIA Australia
- Employees
- ZONE N/A
- KZIA N/A
- Industry
- ZONE
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ZONE
- KZIA Health Care
- Exchange
- ZONE NYSE
- KZIA Nasdaq
- Market Cap
- ZONE 10.3M
- KZIA 6.0M
- IPO Year
- ZONE 2024
- KZIA 1999
- Fundamental
- Price
- ZONE $1.17
- KZIA $0.96
- Analyst Decision
- ZONE
- KZIA Strong Buy
- Analyst Count
- ZONE 0
- KZIA 2
- Target Price
- ZONE N/A
- KZIA $11.50
- AVG Volume (30 Days)
- ZONE 101.7K
- KZIA 384.7K
- Earning Date
- ZONE 02-14-2025
- KZIA 03-26-2025
- Dividend Yield
- ZONE N/A
- KZIA N/A
- EPS Growth
- ZONE N/A
- KZIA N/A
- EPS
- ZONE N/A
- KZIA N/A
- Revenue
- ZONE $1,643,051.00
- KZIA $1,655,324.00
- Revenue This Year
- ZONE N/A
- KZIA N/A
- Revenue Next Year
- ZONE N/A
- KZIA N/A
- P/E Ratio
- ZONE N/A
- KZIA N/A
- Revenue Growth
- ZONE N/A
- KZIA 248000.00
- 52 Week Low
- ZONE $0.87
- KZIA $0.76
- 52 Week High
- ZONE $4.24
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- ZONE N/A
- KZIA 44.72
- Support Level
- ZONE N/A
- KZIA $0.86
- Resistance Level
- ZONE N/A
- KZIA $0.99
- Average True Range (ATR)
- ZONE 0.00
- KZIA 0.13
- MACD
- ZONE 0.00
- KZIA 0.06
- Stochastic Oscillator
- ZONE 0.00
- KZIA 29.41
About ZONE CLEANCORE SOLUTIONS INC
CleanCore Solutions Inc engages in the development and manufacturing of cleaning products that produce pure aqueous ozone for professional, industrial, or home use. The firm has a patented nanobubble technology using aqueous ozone that is effective in cleaning, sanitizing, and deodorizing surfaces and high-touch areas. The company offers products and solutions that are marketed for janitorial and sanitation, ice machine cleaning, laundry, and industrial industries. Its products are used in many types of environments including retail establishments, distribution centers, factories, warehouses, restaurants, schools and universities, airports, healthcare, food service, and commercial buildings such as offices, malls, and stores.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.